Z
Zhiyong Yuan
Researcher at Tianjin Medical University Cancer Institute and Hospital
Publications - 96
Citations - 1488
Zhiyong Yuan is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 16, co-authored 72 publications receiving 938 citations. Previous affiliations of Zhiyong Yuan include Tianjin Medical University.
Papers
More filters
Journal ArticleDOI
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu,Zhen Tao,Bo Hai,Huagen Liang,Ying Shi,Tao Wang,Wen Song,Yong Chen,Jun OuYang,Jinhong Chen,Fanfei Kong,Yishan Dong,Shi Wen Jiang,Weiyong Li,Ping Wang,Zhiyong Yuan,Xiaoping Wan,Chenguang Wang,Wencheng Li,Xiaoping Zhang,Ke Chen +20 more
TL;DR: It is demonstrated that miR-424(322) regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer, and data suggest a biological and functional interaction between PD- L1 and chemoresistance through the microRNA regulatory cascade.
Journal ArticleDOI
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
Zhen Tao,Zhen Tao,Justin M Le Blanc,Chenguang Wang,Tingting Zhan,Hongqing Zhuang,Ping Wang,Zhiyong Yuan,Bo Lu +8 more
TL;DR: The findings suggest that MEK inhibitor in combination with CDK4/6 inhibitor has significant anti-KRAS–mutant NSCLC activity and radiosensitizing effect in preclinical models, potentially providing a novel therapeutic strategy for patients with advanced KRAS-mutants NSCLCs.
Journal ArticleDOI
CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
TL;DR: The tumor microenvironment represents an abnormal niche containing numerous factors, such as T cells, dendritic cells (DCs), regulatory T cells (Tregs), and indoleamine 2,3‐dioxygenase (IDO), involved in maintaining immune homeostasis and tolerance.
Journal ArticleDOI
Factors Affecting the Risk of Brain Metastasis in Small Cell Lung Cancer With Surgery: Is Prophylactic Cranial Irradiation Necessary for Stage I-III Disease?
TL;DR: Stage I SCLC patients with complete resection had a low incidence of brain metastases and a favorable survival rate, and PCI might have a role for stage II-III disease but not for stage I disease.
Journal ArticleDOI
MicroRNA-374b suppresses proliferation and promotes apoptosis in T-cell lymphoblastic lymphoma by repressing AKT1 and Wnt-16
Dong Qian,Dong Qian,Kailin Chen,Haixia Deng,Huilan Rao,Hui Qiang Huang,Yi-Ji Liao,Xiaofei Sun,Suying Lu,Zhiyong Yuan,Dan Xie,Qingqing Cai +11 more
TL;DR: Downregulation of miR-374b was frequently detected in primary T-LBL tissues, which was significantly associated with worse overall survival and increased risk of recurrence of the 58 patients enrolled in this study.